4.1 eHN ePrescription Guidelines revision

Pim Volkert , NL
eHN sg on Semantics - Rapporteur

8 November 2021 (digital) Brussels, Belgium

20th eHN Meeting

eHN sg on Semantics - Governance

Nov 2019 to Oct 2021 (1st mandate)

- **MS-Co-Chair:** Sefanie Weber, DE
- **MS Rapporteur:** Pim Volkert, NL

Nov 2021 to Oct 2023 (2nd mandate)

- **Re-election by unanimous vote in the eHN sg on Semantics**
  - **MS-Co-Chair:** Sefanie Weber, DE
  - **MS Rapporteur:** Pim Volkert, NL

eHealth Network ePrescription Guidelines revision

Topic at stake:

a) **Spring 2021, eHN mandated the sub-group on Semantics to** investigate the revision of the ePrescription guideline and report back to the eHealth Network in its fall meeting.

b) The current state of the ePrescription guideline has been **discussed in several forums** (i.e. UNICOM, ePI, EMA)

c) Subgroup is asking for advice and guidance on the general revision direction

d) The aim is to have a **final draft for approval in the spring 2022** eHealth Network meeting

eHealth Network ePrescription Guidelines revision

Ongoing reflections requiring eHealth Network guidance:

a) **Alignment with Patient Summary guidelines,** as a guiding principle for all kind of implementations (cross-border as well as national)

b) **ePrescription guidelines scope,**
- Medical devices should be in or out of scope of the ePrescription guidelines?
- "Magistral/extemporaneous medicinal product" should remain in scope?

c) **Alignment with electronic Product Information activities (ePI) from EMA**, in overlapping fields and linking ePI to ePrescription in digital applications

d) **ISO IDMP family of standards are great candidates for the preferred vocabularies,** however, the implementation of some of these standards is not widespread, as well as some of the identifiers are not fully specified yet

eHealth Network ePrescription Guidelines revision

Guidance from the eHealth Network is needed regarding:

a) **What is in the scope of the guideline and if the elements out of scope need to be addressed in another guideline as well**
   - Sub-group recommends to keep the scope of the ePrescription guideline limited to authorised medicinal products

a) **Alignment of work with UNICOM, ePI work of EMA and the Patient Summary guideline 3** (inclusion of planned care and possible other use cases that might arise in the future)

b) **A strategic (long term) implementation of the ISO IDMP family of standards is envisioned for, not only regulatory, but as well clinical use cases.**

Questions?

Further information

eHealth Network
https://ec.europa.eu/health/ehealth/policy/network_en

All events
https://ec.europa.eu/health/ehealth/events_en#anchor0